Can-Fite Biopharma (CANF) vs Imunon (IMNN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Can-Fite Biopharma is the larger company by market cap ($6.1 million vs $6.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | CANF | IMNN |
|---|---|---|
| Share price | $2.00 | $1.07 |
| Market cap | $6.06M | $6.00M |
| 1-day change | -4.76% | -4.46% |
| YTD return | -50.00% | — |
| 1-year return | -83.05% | — |
| 5-year return | -99.35% | — |
| EPS (TTM) | $-13.23 | $-3.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.40 | $5.39 |
| 52-week low | $1.96 | $1.04 |
| Distance from 52-week high | -83.87% | -80.15% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +300.00% | +1488.79% |
| Average volume | 387.60K | 153.67K |
| Shares outstanding | 3.03M | 5.61M |
| Employees | 5 | 20 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Can-Fite Biopharma
CANF stock →Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis.
Healthcare · Biotechnology · 5 employees
About Imunon
IMNN stock →Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma.
Healthcare · Biotechnology · 20 employees
CANF vs IMNN FAQ
Which is bigger, Can-Fite Biopharma or Imunon?
Can-Fite Biopharma (CANF) is larger, with a market capitalization of $6.06M compared with $6.00M for Imunon (IMNN).
Are Can-Fite Biopharma and Imunon in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.